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Background: The onset of psychosis is thought to be preceded by neurodevelopmental changes in the brain.
However, the timing and nature of these changes have not been established. The aim of the present study
was to determine whether three “classic” neurophysiological markers of schizophrenia are also characteristic
of young adolescents (12–18 years) at ultra-high risk for psychosis (UHR).
Methods: 63 young UHR individuals and 68 typically developing, age-, sex- and IQ-matched controls were
recruited for neurophysiological assessment. Data for P50 suppression, prepulse inhibition (PPI) and smooth
pursuit eye movements (SPEM) were gathered and compared.
Results: UHR individuals showed reduced PPI compared to controls, which became more pronounced when
controls were directly compared to medication-naive UHR individuals (N=39). There were no group differ-
ences in P50 or SPEM measures.
Conclusions: These results suggest that PPI is a relatively early vulnerability marker, while changes in other
neurophysiological measures may only be detected or affected later during the illness course. Antipsychotic
and antidepressant medication may aid in elevating PPI levels and potentially have a neuroprotective effect.© 2011 Elsevier B.V. Open access under the Elsevier OA license. 1. Introduction
The putative state of disrupted neurobiological function in psy-
chotic disorders is increasingly supported by the identiﬁcation of
illness related biomarkers. Neurophysiological recordings provide
a relatively non-invasive observation method and have shown evi-
dence for aberrant neuronal activity in schizophrenia and related
disorders (Turetsky et al., 2007; Thaker, 2008). It has been suggested
that these abnormalities represent (heritable) traits, rather than state
dependent markers, because they are present in unaffected, ﬁrst-
degree relatives and in individuals in remission of psychosis as well
(Greenwood et al., 2007; Turetsky et al., 2007; Thaker, 2008). How-
ever, the timing of manifestation and predictive validity of these neu-
robiological markers for the subsequent transition to psychosis
remains unknown.
Introduction of the clinical- or ultra-high risk (UHR) design has
helped to identify individuals at increased risk of developing psychosis
on the basis of sub-syndromal symptoms (Wood et al., 2003). Com-
pared to the general population the eventual incidence of psychosis
is high in UHR studies and conversion occurs in relative closence, Retzius Väg 8, Karolinska
86 372.
vier OA license. proximity of initial intake (Cannon et al., 2008; Yung et al., 2008).
Neurophysiological studies in adult UHR individuals have supported
the notion that schizophrenia markers are already present before the
onset of psychosis (Brockhaus-Dumke et al., 2005; Nieman et al.,
2007; Bramon et al., 2008; Brockhaus-Dumke et al., 2008; Frommann
et al., 2008; Ozgurdal et al., 2008; Quednow et al., 2008; van Tricht
et al., 2010a; van Tricht et al., 2010b), and may become more pro-
nounced in those who continue to develop psychosis (Nieman et al.,
2007; Brockhaus-Dumke et al., 2008; van Tricht et al., 2011). This sug-
gests that a progressive worsening of prodromal symptoms is associ-
ated with neurophysiological changes. However, if such changes
precede the onset of psychosis, these should be present in the at-risk
period irrespective of the age of onset. Only a few previously pub-
lished studies have also included young adolescents at UHR and the
outcomes of these studies were partially at odds with each other
(Myles-Worsley et al., 2004; Cadenhead et al., 2005), leaving it unclear
whether altered neurophysiological measures can be detected at an
early stage in life.
To address this issue, the current study investigated three well-
established neurophysiological measures, typically abnormal in
schizophrenic individuals, in a sample of young adolescents at UHR
for psychosis (aged 12–18 years): P50 suppression, prepulse inhibi-
tion (PPI) and smooth pursuit eye movement (SPEM). We hypothe-
sized that the UHR group would show reduced P50 suppression and
Table 2
Demographics and symptom scores ultra-high risk individuals and controls.
UHR Controls Statistic
(n=63) (n=68)
Sex, M/F (%M) 38/25 (60) 31/37 (46) χ2=2.87, p=0.09
Handedness, R/L/M (%R) 58/3/2 (92) 62/3/3 (91) χ2=1.78, p=0.78
Total IQ, mean (sd) 100 (13) 104 (11) t=−1.71, p=0.09
Age, mean (sd) 15.7 (2.1) 15.5 (1.7) t=1.05, p=0.36
SIPS total score, mean (sd) 27.1 (13.9) 2.1 (2.9) U=18.5, pb0.001
BSABS total score, mean (sd) 22.8 (15.2) 1.2 (1.6) U=81.0.14, pb0.001
GAF-score, mean (sd) 57.2 (15.0) 94.4 (13.0) U=115.0, pb0.001
UHR criterium, n (%)
1. APS 57 (90) NA NA
2. BLIPS 3 (5)
3. GRD 2 (3)
4. COGDIS 34 (54)
Smokinga, n (%)
– none 44 (71) 64 (97) χ2=16.66, pb0.001
– occasional 4 (6) 0 (0)
– regular 14 (23) 2 (3)
Current medication2, n (%) NA
– any 24 (38) NA
– atypical antipsychotic 13 (21)
– antidepressant 8 (13)
– psychostimulant 3 (5)
– other
Cannabis use, n (%) 1 (2) NA
– never used 52 (83) NA
– last regular use3>1 month 7 (11)
– regular useb1 month 4 (6)
a Data missing for 1 UHR and 2 controls; 2 regular medication only; 3 more than once
a week; UHR=ultra high risk (total group); M/F=male/female; R/L/M=right/left/
mixed; NA=not applicable; SIPS=Structured Interview for Prodromal Symptoms;
BSABS=Bonn Scale for the Assessment of Basic Symptoms; GAF=Global Assessment
of Functioning.
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expected that the UHR group would show an increase in number of
saccades and a decreased velocity gain.
2. Method
2.1. Subjects
Sixty-three adolescents meeting at least 1 of 4 criteria for UHR
(Table 1) were referred by general practitioners or other psychiatric
clinics and included in this study. These criteria have previously
been published (Sprong et al., 2008; Ziermans et al., 2009) and are
similar to frequently used criteria for UHR (Olsen and Rosenbaum,
2006). The control group consisted of 68 typically developing adoles-
cents. The ﬁrst three inclusion criteria were assessed with the Struc-
tured Interview for Prodromal Syndromes (McGlashan et al., 2001).
The fourth inclusion criterion was assessed with the Bonn Scale for
the Assessment of Basic Symptoms-Prediction List (Schultze-Lutter
and Klosterkötter, 2002).
Sixty-eight typically developing controls were recruited from sec-
ondary schools in the region of Utrecht. They were excluded if they
met one of the UHR-criteria, if they or any ﬁrst degree relative had
a history of any psychiatric illness, or if there was a second-degree
relative with a psychotic disorder.
Groups were matched for age, gender, IQ and handedness
(Table 2). All participants had Dutch nationality and were aged be-
tween 12 and 18 years. Subjects were excluded if there was evidence
of any past or present neurological disorder (e.g. epilepsy). Drug- and
alcohol abuse were additional exclusion criteria although UHR
subjects were permitted a history of drug use, if symptoms had also
been present in the absence of drugs. Figures on (self-reported)
smoking, cannabis use and psychopharmacological medication use
are provided in Table 2. All individuals had a level of verbal intellectu-
al functioning (VIQ)≥75, as assessed with the Wechsler Intelligence
Scales (Wechsler, 1997, 2002). Each individual signed an informed
consent and for those younger than 16, parents co-signed. This
study was approved by the Dutch Central Committee on Research In-
volving Human Subjects.
2.2. Stimulus presentation
Subjects were seated upright in an acoustically shielded room, 1
meter (measured from the position of the eyes) in front of a 21-inch
computer screen on which visual stimuli were presented. Auditory
stimuli were presented binaurally through stereo insert earphones
(Eartone ABR). Software settings were calibrated by an artiﬁcial ear
(Brüel and Kjær, type 4152) to ensure adequate stimulus intensities.
2.3. Recordings
Recordings were obtained from 32 AgAgCl electrodes using a Bio-
Semi Active Two EEG system (Biosemi, Amsterdam). For the P50
measurement, EEG was sampled at 2048 Hz, referenced to an addi-
tional active electrode (Common Mode Sense) during recording,
and stored as a continuous signal. An electrode placed on the leftTable 1
Ultra high risk criteria.
1. Attenuated positive symptoms (APS)
2. Brief, limited or intermittent psychotic symptoms (BLIPS)
3. 30% Reduction in overall level of social, occupational/school-, and psychologi-
cal functioning (i.e. GAF-score) in the past year, combined with a genetic risk
of psychosis (i.e. having a ﬁrst- or second-degree relative with an established
psychotic disorder) (GRD)
4. Two or more of a selection of nine basic symptoms, i.e. subjective deﬁcits in
cognitive, perceptual, and motor functioning (COGDIS)mastoid was used as off-line reference for EEG measurement. For
PPI, electromyographic (EMG) activity of the right orbicularis oculi
muscle was recorded from bipolar electrodes. One was placed over
the medial aspect of the muscle and one displaced 0.5 cm laterally.
Horizontal and vertical eye movements were recorded using
electro-oculography (EOG) to obtain SPEM information. PPI and P50
data were analyzed using the software package Brain Vision Analyzer
(Brain Products, München).
2.4. Experimental paradigms
Paradigms used in this study have been described in previous pub-
lications (Magnee et al., 2009; Vorstman et al., 2009; van Rijn et al.,
2011; Ziermans et al., 2011a). Abbreviated descriptions of paradigms
are given below and additional details are provided in the Supple-
mentary Information.
2.4.1. P50 suppression
A block of 36 click pairs (86 dB, 1.5 ms duration white noise) was
presented, with an interstimulus interval of 500 ms and an intertrial in-
terval of 10 s. Subjects were instructed to count click pairs and report
thenumber afterwards. The P50 ratiowas calculated for theCz electrode
as the amplitude of the P50 potential elicited by the testing stimulus
divided by the amplitude elicited by the conditioning stimulus (T/C).
2.4.2. Prepulse inhibition
The experiment consisted of 24 randomized trials: 12 startle stim-
uli preceded by a prepulse and 12 startle stimuli with no prepulse.
The prepulse and startle stimuli were bursts of white noise (duration
22.5 and 32.5 ms, intensity 87 and 106.5 dB, respectively, rise/fall
0.1 ms) over a 30 dB background noise, with a ﬁxed interstimulus in-
terval of 120 ms. The intertrial interval varied between 12 and 23 s. %
PPI was deﬁned as the percentage of reduction of the startle
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als (PPI=100(1−pp/p)), where pp indicates amplitude over pre-
pulse trials and p indicates amplitude over pulse alone trials.
2.4.3. Smooth pursuit eye movements
The target was a small, but clearly visible, white moving dot (2 by
2 pixels) on a uniform dark-gray background. There were seven trials,
each consisting of 5 movements of the dot from left to right and back
again with amplitude from left to right of 20° of visual angle. In each
trial the dot moved at a constant velocity (sinusoidal motion). Stimu-
lus velocities of 8, 13, 16, 20, 24, 29, and 35°/s were used, and in this
order. Saccades are deﬁned as a period of absolute velocity above
35°/s between two successive acceleration peaks of opposite sign. Ve-
locity gain (VG) is deﬁned as mean eye velocity divided by target ve-
locity. For each of the seven frequencies presented, the VG and the
number of saccades (NSAC) were calculated. No absolute position of
gaze information was available, so it was not possible to determine
saccadic type (anticipatory, leading, catch-up etc.).
2.5. Data analysis
Comparison of group characteristics was performed using Stu-
dent's t-tests for age and IQ scores, χ2-test for gender distribution and
smoking status and Mann–Whitney U tests for clinical scores (pb0.05,
two-tailed). Dependent variables for the neurophysiological paradigms
were: P50 ratio, %PPI, and, for SPEM, VG and NSAC per frequency. For
each dependent measure, extreme outliers (>3 standard deviations
from the mean) were removed. To check for the occurrence of main ef-
fects of stimuli within- and between-subjects, a mixed-model analysis
of variance (ANOVA) was used for all paradigms. For PPI, startle ampli-
tudes were log-transformed to diminish the effect of a skewed distribu-
tion. %PPI was calculated by using the absolute startle amplitudes.
Greenhouse–Geisser corrections were used for SPEM measures in case
the assumption of sphericity was violated. ANOVA was applied to test
for differences between groups on P50 ratio and %PPI. Group analyses
were repeated with medicated individuals excluded from the total
UHR sample, to control for potential medication effects. Results were
considered signiﬁcant if pb0.05, two-tailed.
3. Results
3.1. Group characteristics
Details are given in Table 2. Total groups were matched for age,
sex and TIQ. Subsequent exclusion of individuals did not affect statis-
tical matching.Fig. 1. P50 auditory evoked potential of Cz-electrode site in response to the conditioning (C-
risk (UHR) group (middle) and an overlay of the waveforms (right).3.2. P50 suppression
Due to incomplete data and technical errors, data from 5 control
subjects and 1 UHR subject were excluded. Three data outliers (two
controls, one UHR) were also excluded. Within-subjects there was
signiﬁcant P50 suppression (F(1,120)=126.99, p≤0.001; Fig. 1), il-
lustrated by a smaller positive response on T stimulus (controls:
M=1.3, sd=1.3; UHR M=1.0, sd=1.1) compared to C stimulus
(controls: M=3.1, sd=2.0; UHR M=2.7, sd=1.6), but no effect be-
tween groups. Additionally, there were no differences between
groups for P50 ratio. Repeated analyses with unmedicated UHR sub-
jects only (n=39) yielded similar results.3.3. Prepulse inhibition
Three subjects (1 control, 2 UHR) were excluded based on incom-
plete data or technical errors. Additionally, 5 data outliers (3 controls,
2 UHR) were removed from the analyses. PPI suppression was ob-
served within-subjects (F(1,121)=350.27, pb0.001), reﬂecting
greater absolute startle magnitude for pulse alone (controls:
M=30.27, sd=28.5; UHR M=32.87, sd=32.2) than for prepulse
stimuli (controls: M=8.63, sd=11.4; UHR M=12.97, sd=13.0).
There was a signiﬁcant PPI X group interaction (F(1,121)=5.06,
p=0.045), suggesting greater inhibition for controls compared to
UHR individuals. When all medicated individuals were excluded (37
UHR remaining), the PPI X group interaction remained signiﬁcant
(F(1,99)=7.10, p=0.009; Fig. 2A). In line with these results, there
was a signiﬁcant overall group effect for %PPI (based on absolute am-
plitudes), with UHR individuals displaying signiﬁcantly lower %PPI
than the control group (F(1,122)=4.31, p=0.040). After exclusion
of medicated UHR individuals this effect became more signiﬁcant
(F(1,99)=7.40, p=0.010; see Fig. 2B). In all analyses pulse alone am-
plitude was checked for potential confounding inﬂuence and did not
differ between UHR individuals and controls.3.4. Smoot pursuit eye movements
Data was incomplete or of insufﬁcient quality for 16 subjects (8
UHR, 8 controls) and one outlier (UHR) was excluded from NSAC ana-
lyses. A main effect of frequency within-subjects was found for VG
(F(3.7,420.9)=551.39, pb0.001) and NSAC (F(2,220.1)=173.45,
pb0.001). Both groups displayed a similar pattern for VG and NSAC
per frequency factor (Fig. 3). Repeated analyses for controls versus
unmedicated UHR individuals only (n=35) did not affect the
outcome.stimulus) and testing stimuli (T-stimulus) in the control group (left) and the ultra-high
Fig. 2. A. Error bars (mean±1 standard error) of the log-transformed startle amplitudes for pulse alone and prepulse stimuli. The left panel shows data for the total control and
ultra-high risk groups and in the right panel medicated individuals have been excluded from the UHR group. B. Total percentage prepulse inhibition for UHR individuals based
on medication type. AD=antidepressant; AP=antipsychotic; St=psychostimulant; AC=anticonvulsant (used as mood stabilizer).
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Paradigmswere checked for potential confounders using themixed-
linear models. When sex, age and TIQ were entered as covariates,
results remained unchanged for P50. PPI showed signiﬁcant within-
subject interactions for age (F(1,118)=4.71, p=0.032) and TIQ
(F(1,118)=7.42, p=0.007), with higher age and TIQ associated with
greater PPI, predominantly due to an increase in pulse alone amplitude.0.0
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Fig. 3. Smooth pursuit eye movements as a function of velocity gain (left) and number of sa
veloping controls (blue).Interaction with group was no longer signiﬁcant (p=0.07) and there
were no between-group differences. In the medication naive-groups
PPI×TIQ remained signiﬁcant (F(1,96)=10.55, p=0.002) and the
group effect re-appeared (F(1,96)=5.74, p=0.019). Group compari-
sons were unchanged for SPEM measures, but there was a signiﬁcant
interaction for the medication-naive group comparison of NSAC×age
(F(2,166.3)=3.76, p=0.026), showing a decrease in NSAC with in-
creasing age, independent of stimulus velocity.0.0
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ccades per second (right) for ultra-high risk (UHR) individuals (red) and typically de-
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Inﬂuence of smoking status and cannabis use was tested for UHR
individuals only, by adding these variables as between-subjects fac-
tors. For both variables substance-naive individuals were compared
to exposed individuals (see Table 2). No group differences were
found based on smoking status or cannabis use.
4. Discussion
This study set out to investigate whether commonly reported neu-
rophysiological markers of the schizophrenia spectrum are also char-
acteristic of the psychosis prodrome during adolescence. Three
“classical” paradigms were assessed in a large group of adolescents
at ultra-high risk (UHR) for psychosis and typically developing con-
trols. Results showed that prepulse inhibition (PPI) was affected and
signiﬁcantly reduced in UHR individuals compared to controls. This
group difference became more apparent when controls were directly
compared with medication-naive UHR individuals.
A previous study investigating acoustic PPI using similar UHR inclu-
sion criteria in adult individuals, demonstrated a clear reduction in PPI
for both prodromal individuals and unmedicated schizophrenics
(Quednow et al., 2008). However, two recent longitudinal PPI studies
(Cadenhead, 2011; Ziermans et al., 2011a) have shown mixed results
regarding whether reduced PPI is a consistent vulnerability marker
over time in UHR individuals, possibly due to differences in paradigms
(e.g. interstimulus interval, background noise, number of trials) or con-
founding factors such as age, sex, IQ, substance use or medication. Re-
garding medication, the greater reduction of PPI found in medication-
naive individuals in this study strengthens the idea that PPI is potentially
normalized by psychopharmaceutical medication (Kumari and Sharma,
2002; Oranje et al., 2008), particularly for antipsychotic and antidepres-
sant medication (see Fig. 2B).
The results of the present study indicate that PPI qualiﬁes as a neu-
robiological vulnerability marker in adolescence. It has been sug-
gested that there are quantitative and qualitative changes in the
developmental course of neurophysiological measures towards
young adulthood (Wetzel et al., 2006). Interestingly, in this study
we found an interaction between PPI and age, showing that level of
PPI increases with age, particularly in UHR individuals. If neurobiolog-
ical vulnerability markers are characteristic of the psychosis pro-
drome, then during young adolescence detection might be hindered
by late maturational processes of the brain (Shaw et al., 2008). The
presence of PPI reductions in UHR adolescents suggests, however,
that subtle brain changes related to the disease process may already
manifest at the level of the cortico–striato–pallido–thalamic (CSPT)
circuitry responsible for PPI (Braff et al., 2001; Swerdlow et al.,
2001), before large structural brain changes in temporal and frontal
gray matter volume, observed in UHR adults (Smieskova et al.,
2010), become more apparent.
Our results for auditory P50 suppression are in agreement with a
previous study (Cadenhead et al., 2005) that failed to ﬁnd an overall
group difference between controls and adolescents at risk. However,
earlier study results in medication-naive UHR adolescents reported
a reduced P50 suppression, especially for those with a ﬁrst degree rel-
ative with schizophrenia (Myles-Worsley et al., 2004). Comparison
across these two studies and ours is partially restricted however,
due the large differences in age range per study (4–18 years). More
recently, evidence was reported for a P50 suppression deﬁcit in
antipsychotic-naïve UHR-adults (mean age: 23.5 years) (Brockhaus-
Dumke et al., 2008). Changes were more pronounced in those with
subsequent transition to psychosis within two years after inclusion,
although they were also present in those without transition. A limita-
tion of this study was that the groups were not well matched for size,
age or IQ. Taken together, the available studies in individuals at risk
are inconclusive about whether reduced P50 suppression can beconsidered a vulnerability marker during early development. Howev-
er, the studies above have also shown data that suggests that a genet-
ic high risk combined with clinical symptoms increases the chance of
detecting sensory gating changes.
In our study we did not ﬁnd evidence for abnormal SPEM mea-
sures in UHR individuals. One previous study investigated SPEM in
adolescent and young adult UHR individuals and found that these in-
dividuals had higher number of corrective and non-corrective sac-
cades than controls, but no differences in smooth pursuit gain (van
Tricht et al., 2010a). Although we were unable to ﬁnd group differ-
ences in NSAC in our sample, our SPEM method only looked at hori-
zontal eye movements and could not distinguish between corrective
and non-corrective saccades, unlike the method use by van Tricht et
al. Additionally, a large study comparing a group of genetic high-
risk children to healthy controls and individuals with childhood
onset schizophrenia showed that only the latter group had saccadic
abnormalities (Ross et al., 2005). Similarly, our results suggest that
some SPEM abnormalities may potentially be more descriptive of
the psychotic state itself than of the preceding period.
Although no gross abnormalities were found for P50 suppression
and SPEM, it does not imply a lack of use for these paradigms in
high-risk research. The main reason for including these particular
markers in our study was because of their frequently replicated devi-
ance scores in individuals with schizophrenia spectrum disorders and
the lack of knowledge about their onset. However, neurophysiological
parameters are sensitive measures and the use of slightly modiﬁed
paradigms or alternative parameters could have yielded different re-
sults. For example, number of stimuli/epochs was kept relatively low
in our paradigms due to time constraints and may have decreased the
signal-to-noise ratio. For PPI and P50 we used peak averages as op-
posed to trial-by-trial measures, preventing analyses of sensitization
and habituation effects (Halberstadt and Geyer, 2009). Furthermore,
during the P50 assessment participants had to count click pairs,
which may have modulated the attention of participants in an unfa-
vorable way for detecting gating differences (Yee et al., 2010). There-
fore, follow-up data using identical paradigms are needed to
determine whether additional changes occur alongside clinical im-
provement or deterioration in UHR individuals.
Presence of a psychotic transition in our UHR individuals was
monitored during a 2-year follow-up study (Ziermans et al., 2011b).
Within the current study eight (13%) UHR individuals had experi-
enced a psychotic transition. However, statistical restrictions did not
allow for meaningful, unbiased group analyses. Visual inspection of
the data (see Supplementary Information) suggested that, besides a
further reduction of PPI, UHR individuals with subsequent psychosis
might also show impaired position gain during the smooth pursuit
task compared to controls and UHR individuals without psychosis.
These ﬁndings should be interpreted with caution and conﬁrmed in
larger samples of individuals with a psychotic conversion or in longi-
tudinal studies (Cadenhead, 2011; van Tricht et al., 2011; Ziermans et
al., 2011a).
In conclusion, this study has provided evidence for changes in PPI,
but not P50 gating or SPEM, in a group of young adolescents at risk for
psychosis compared to typically developing controls. Reduced PPI
may therefore represent one of the earliest vulnerability markers for
psychosis, although follow-up studies are required to determine its
speciﬁcity to a particular clinical phenotype. Furthermore, psycho-
pharmaceutical medication may partially obscure the presence of
PPI reductions by normalizing the auditory startle response. Negative
ﬁndings for P50 and SPEM in this study may be reﬂective of subopti-
mal recording procedures, unaddressed confounders or brain matura-
tional processes with the ability to detect vulnerability markers at
this age. Alternatively, these markers could be more closely related
to the actual onset of psychosis than a high-risk state. Additional re-
sults from longitudinal and multi-method neuroimaging studies are
required to rule out some of these explanations.
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